KYORIN Pharmaceutical Co., Ltd. Logo

KYORIN Pharmaceutical Co., Ltd.

A research-based pharmaceutical company that develops and sells prescription and generic drugs.

4569 | T

Overview

Corporate Details

ISIN(s):
JP3247090008
LEI:
Country:
Japan
Address:
千代田区大手町一丁目3番7号

Description

KYORIN Pharmaceutical Co., Ltd. is a research-based pharmaceutical company engaged in the research, development, manufacturing, and sale of prescription (ethical) and generic drugs. The company's commercial and R&D activities are focused on key therapeutic areas, including respiratory medicine, urology, otolaryngology (ENT), and inflammatory bowel disease (IBD). Through its subsidiaries, such as KYORIN Rimedio Co., Ltd., it also handles the manufacturing and distribution of generic medicines. The company is committed to providing a stable supply of high-quality pharmaceutical products to medical institutions and patients.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 07:42
確認書
Japanese 8.9 KB
2025-11-13 07:36
半期報告書-第68期(2025/04/01-2025/09/30)
Japanese 220.9 KB
2025-06-26 07:25
臨時報告書
Japanese 23.5 KB
2025-06-19 08:55
内部統制報告書-第67期(2024/04/01-2025/03/31)
Japanese 27.1 KB
2025-06-19 08:53
確認書
Japanese 8.9 KB
2025-06-19 08:50
有価証券報告書-第67期(2024/04/01-2025/03/31)
Japanese 1.4 MB
2024-11-13 07:27
確認書
Japanese 8.9 KB
2024-11-13 07:24
半期報告書-第67期(2024/04/01-2025/03/31)
Japanese 216.2 KB
2024-06-28 08:30
臨時報告書
Japanese 23.5 KB
2024-06-24 08:53
内部統制報告書-第66期(2023/04/01-2024/03/31)
Japanese 24.3 KB
2024-06-24 08:51
確認書
Japanese 8.9 KB
2024-06-24 08:47
有価証券報告書-第66期(2023/04/01-2024/03/31)
Japanese 1.3 MB
2024-02-14 07:07
確認書
Japanese 8.9 KB
2024-02-14 07:05
四半期報告書-第66期第3四半期(2023/10/01-2023/12/31)
Japanese 190.9 KB
2023-11-14 07:36
確認書
Japanese 8.2 KB

Automate Your Workflow. Get a real-time feed of all KYORIN Pharmaceutical Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for KYORIN Pharmaceutical Co., Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for KYORIN Pharmaceutical Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

4BASEBIO PLC Logo
Manufactures GMP-grade synthetic DNA for next-generation therapeutics and vaccines.
United Kingdom
4BB
4D Molecular Therapeutics, Inc. Logo
Develops genetic medicines using AAV vectors for ophthalmology and pulmonology diseases.
United States of America
FDMT
4SC AG Logo
Biopharmaceutical company with no products under development or operational business.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops and commercializes medicines for infectious diseases, focusing on tropical illnesses.
United States of America
SXTP
89bio, Inc. Logo
Clinical-stage biopharma developing therapies for liver and cardiometabolic diseases.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Clinical-stage biopharma developing therapeutics for hunger and metabolic diseases.
United States of America
AARD
ABBOTT LABORATORIES Logo
Global healthcare company in medical devices, diagnostics, nutrition & pharmaceuticals.
United States of America
ABT
AbbVie Inc. Logo
A research-based biopharmaceutical company developing and manufacturing medicines.
United States of America
ABBV
AbCellera Biologics Inc. Logo
Discovers and develops antibody-based therapeutics using a proprietary platform.
United States of America
ABCL
Develops antibody-based therapeutics using CAR-T, NEST, and AffiMab platforms.
South Korea
174900

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.